Kevin L Stephans

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT)
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 82:974-80. 2012
  2. ncbi Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Oncol 4:838-44. 2009
  3. ncbi The current status of image-guided external beam radiotherapy for prostate cancer
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Urol 20:223-8. 2010
  4. ncbi Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 78:1033-9. 2010
  5. ncbi A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience
    Kevin L Stephans
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Oncol 4:976-82. 2009
  6. ncbi The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?
    Gregory M M Videtic
    Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 12:235-41. 2010
  7. ncbi Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes
    Neil M Woody
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
    Int J Radiat Oncol Biol Phys 83:427-34. 2012
  8. ncbi Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy
    Rahul D Tendulkar
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Int J Radiat Oncol Biol Phys 82:1397-404. 2012

Collaborators

Detail Information

Publications8

  1. ncbi Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT)
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 82:974-80. 2012
    ..To determine patient, tumor, and treatment factors related to the development of late chest wall toxicity after lung stereotactic body radiotherapy (SBRT)...
  2. ncbi Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Oncol 4:838-44. 2009
    ..To assess for variables predicting pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for medically inoperable stage I lung cancer...
  3. ncbi The current status of image-guided external beam radiotherapy for prostate cancer
    Kevin L Stephans
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Opin Urol 20:223-8. 2010
    ..To assess the current status and technological advances in image-guided external beam radiotherapy for prostate cancer...
  4. ncbi Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 78:1033-9. 2010
    ....
  5. ncbi A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience
    Kevin L Stephans
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Oncol 4:976-82. 2009
    ..To assess the impact of fractionation upon tumor control and toxicity in medically inoperable early stage lung cancer patients treated with stereotactic body radiotherapy...
  6. ncbi The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?
    Gregory M M Videtic
    Cleveland Clinic Lerner College of Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 12:235-41. 2010
    ..Ongoing prospective trials are exploring dose and fractionation schedules in the inoperable population, and are starting to explore the role of SBRT for the operable patient...
  7. ncbi Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes
    Neil M Woody
    Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
    Int J Radiat Oncol Biol Phys 83:427-34. 2012
    ..This study developed a predictive model of chest wall pain incorporating radiobiologic effects, using clinical data from four distinct SBRT fractionation schemes...
  8. ncbi Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy
    Rahul D Tendulkar
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Int J Radiat Oncol Biol Phys 82:1397-404. 2012
    ..Modern outcomes of high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT) for high-risk (HR) prostate cancer are not well described...